HCT Graft Source Selection Guidelines: DSA and Virtual Crossmatch
Recording date: Dec. 2, 2021
As hematopoietic cell transplantation (HCT) has evolved with the selection of mismatched donors, donor-specific HLA antibodies (DSA) must be considered to reduce the risk of primary graft failure. A new virtual crossmatch (VXM) tool in MatchSource® can now aid in selection of unrelated donors and cord blood units if the patient has HLA antibody specificities.
This webinar will highlight the impact of DSA on transplant outcomes, as well as provide a brief overview of the VXM tool in MatchSource.
During this webinar, attendees will grow their knowledge and understanding of how to:
- Recognize the impact of donor-specific HLA antibodies on transplant outcomes
- Describe the HLA laboratory’s role in HLA antibody testing and interpretation
- Use the virtual crossmatch tool in MatchSource to avoid donors and cords with HLA mismatches targeted by DSA
Coordinators, physicians and medical directors at transplant centers
- Medhat Askar, MD, PhD
Director of Clinical Services, National Marrow Donor Program® (NMDP)/Be The Match®
- Brian Shaffer, MD
Hematologist, Memorial Sloan Kettering Cancer Center
- Lucas Nacusi, PhD
Senior Immunogenetic Specialist, NMDP/Be The Match